IndraLab
Statements
Hydroxychloroquine activates onset disease. 1 / 1
|
1
eidos
"Chloroquine and hydroxychloroquine are approved for the treatment of SLE and have been shown to reduce the frequency of disease flares ( particularly of lupus nephritis ) , contribute to the maintenance of remission , prolong the onset of disease and reduce the risk of complications.1 ,2,3,4,5 Beyond their immunomodulatory effects in SLE , these agents have also been shown to protect against thrombotic events ,2 improve glucose and lipid profiles , and prevent renal damage ,6 apparently resulting in reduced cardiovascular risk , for which SLE is an independent risk factor ."